Drug Information Association Logo

Advanced Search

MM-DD-YYYY

Browse Articles

Search Articles 

Publication Title Author Date Volume Abstract
DIAJ Benefit/Risk Estimates in Clinical Trials Adil E. Shamoo 2011 45(05) View Abstract
DIAJ Japanese Guideline on Global Clinical Trials: Statistical Implications and Alternative Criteria for Assessing Consistency Florence Le Maulf,Kevin J. Carroll 2011 45(05) View Abstract
DIAJ Decision Making for a Companion Diagnostic in an Oncology Clinical Development Program Bernard Fine,Lee Kaiser 2011 45(05) View Abstract
DIAJ Establishing a Complete Drug Information Triad: Academic, Industry, and Hospital Training Elizabeth S Miller,Katie J. Suda,Anne M. Hurley,Mina Tadrous,Daniel Gharbawy 2011 45(05) View Abstract
DIAJ Reporting of Adverse Drug Reactions by Community Pharmacists: A Qualitative Study in Quebec Benoit Rouleau 2011 45(05) View Abstract
DIAJ Technical Requirements for Biopharmaceutics Classification System–based Biowaiver in China Ning Zhang 2011 45(05) View Abstract
DIAJ Results of a Survey of PhRMA Member Companies on Practices Associated With Multiregional Clinical Trials Nick R Scott,Tonya L Houck,Yoko Tanaka,Bruce Binkowitz,Belinda Field,Ekopimo O. Ibia,Andy Lee,Steven Talerico 2011 45(05) View Abstract
DIAJ Consistency of Treatment Effect Across Regions in Multiregional Clinical Trials, Part 2: Monitoring, Reporting, and Interpretation Soo Ouyang,Paul P. Gallo,Shailendra S. Menjoge,Yoko Tanaka,Bruce Binkowitz,Ekopimo O. Ibia,Gang Li,Hui Quan,Xiaolong Luo,Joshua Chen,Steven Talerico,Kimitoshi Ikeda 2011 45(05) View Abstract
DIAJ Optimal Allocation of Prognostic Factors in Randomized Preclinical Animal Studies Zheng Su 2011 45(06) View Abstract
DIAJ Optimal Allocation of Prognostic Factors in Randomized Preclinical Animal Studies 2011 45(06) View Abstract
DIAJ Review of: Fundamentals of US Regulatory Affairs, 7th ed. Edward Tabor 2011 45(06) View Abstract
DIAJ Certification for the Medical Science Liaison: An Idea Whose Time Has come---or Not Kenneth L Massey,Jane Chin,Jimmy Thomas Black 2011 45(06) View Abstract
DIAJ Medical Information Services in the Age of Social Media and New Customer Channels Lesley S. Fierro,Poonam A. Bordoloi,Michelle Clausen,Krupa Paranjpe,Andrew Gazo 2011 45(06) View Abstract
DIAJ Clinically Important Effects in New Drug Development Satoshi Hashigaki,Kanae Togo,Takashi Moriya,Keiji Imai 2011 45(06) View Abstract
DIAJ Consistency of Treatment Effect Across Regions in Multiregional Clinical Trials, Part 1: Design Considerations Soo Ouyang,Paul P. Gallo,Shailendra S. Menjoge,Yoko Tanaka,Bruce Binkowitz,Ekopimo O. Ibia,Gang Li,Hui Quan,Xiaolong Luo,Joshua Chen,Steven Talerico,Kimitoshi Ikeda 2011 45(05) View Abstract
DIAJ Assessment of Electronic Drug Information Research Availability in Alabama Pharmacies Michael G Kendrach,Bob Schrimsher,Maisha Kelly Freeman 2011 45(06) View Abstract
DIAJ Content Analysis of Off-label Drug Use: Reporting Print Media Coverage David A. Holdford,Avani D Joshi 2011 45(06) View Abstract
DIAJ Failure to Communicate: Medication Guide or Memory ? Louis A Morris,Morris S Whitcup 2011 45(06) View Abstract
DIAJ Evaluation of Drug Adverse Event Intake and Reporting in a Medical Information Service Robert Fuentes,Michael Hoopes,Gregory M Susla,Pamela D Allen 2011 45(06) View Abstract
DIAJ Impact of Different Regulatory Requirements for Trial Endpoints in Multiregional Clinical Trials Cynthia J. Girman,Shailendra S. Menjoge,Bruce Binkowitz,Carmen Mak,Anupam Agarwal,Ekopimo O. Ibia,Joshua Chen 2011 45(05) View Abstract
DIAJ Validation of Decision-enabling Tools: Showing That the Model Is Useful Stig J Wiklund 2011 45(06) View Abstract
DIAJ Points to Consider in Defining Region for a Multiregional Clinical Trial: Defining Region Work Stream in PhRMA MRCT Key Issue Team Michael A Rabbia,Yoko Tanaka,Bruce Binkowitz,Carmen Mak,Ekopimo O. Ibia,Brent Burger,Joshua Chen,Alex Zolotovitski 2011 45(05) View Abstract
DIAJ A Benefit-risk Model to Facilitate DMC-sponsor Communication and Decision Making Andreas I. Sashegyi 2011 45(06) View Abstract
DIAJ Letter to the Editor: Selection of the Time Points for a Thorough QTc Study Norman Stockbridge,Joanne Zhang 2011 45(06) View Abstract
DIAJ Multiregional Clinical Trials: An Introduction From an Industry Perspective Bruce Binkowitz,Ekopimo O. Ibia 2011 45(05) View Abstract
DIAJ A Longitudinal Model and Graphic for Benefit-risk Analysis, With Case Study Jonathan D. Norton 2011 45(06) View Abstract
DIAJ Letters to the Editor Norman Stockbridge,Lawrence Z Satin,Eoin O'Brien 2011 45(05) View Abstract
DIAJ Platelet Aggregation Quality Control in a Multicenter Phase 2 Clinical Trial James McRedmond 2011 45(06) View Abstract
DIAJ Program Chair Reflects Upon DIA 2011 Kenneth A. Getz 2011 45(05) View Abstract
DIAJ Ten-year Experience of the Evaluation of Ethnic Sensitivity Data Chia-Ling Hsiao 2011 45(06) View Abstract
DIAJ Editor's Commentary: Letters to the Editor, a New Publishing Partner, and Benefit-risk Estimation Rick Turner 2011 45(05) View Abstract
DIAJ Letter to the Editor 2011 45(06) View Abstract
DIAJ Fewer Drugs, Shorter Lives, Less Prosperity: The Impact of Comparative Effectiveness Research on Health and Wealth Peter J. Pitts 2011 45(06) View Abstract
DIAJ Preparing for a Safety Inspection Steve Jolley 2011 45(06) View Abstract
DIAJ Associate Editor's Commentary: The Danger of Shorting Drug Shortages Peter J. Pitts 2011 45(06) View Abstract
DIAJ Commentary: The Real-world Convergence of Comparative Effectiveness Research and Risk- Benefit Assessment John Doyle 2011 45(06) View Abstract
DIAJ Editor's Commentary: A Time for Reflection and Anticipation Rick Turner 2011 45(06) View Abstract
DIAJ DIA 2011 47th Annual Meeting Student Poster Abstracts Nicholas H. Schluterman,Anne-Sophie Auroux,Ph. Mohammed Hamdan Al Rubaie,Jie Rena Sun,Jingjing Liu,Kaushal Vinaykumar Sheth,Gabriel Meister,Brian Claggett,Danish Arora,Manasi Datar,Shaunak Praful Kulkarni,Michelle P. Pernice,Andrew W. York,Digvijay Chandrakant Yeola,Joseph Mburu,Nikita Somani 2011 45(04) View Abstract
DIAJ Expediting Patient Access to New Medicines: A Call to Action, London, January 26-27, 2010 Peter J. Pitts,Werner Cautreels,Mary Baker 2011 45(04) View Abstract
DIAJ 5th Annual Cardiovascular Risk Assessment Summit Lawrence Z Satin,David E. Gutstein 2011 45(04) View Abstract
DIAJ Review of the 9th Middle East Regulatory Conference Adrian Ball,Mike Stuart Fallows 2011 45(04) View Abstract
DIAJ Review of International Pharmaceutical Product Registration, 2nd ed. Edward Tabor 2011 45(04) View Abstract
DIAJ Implementation of an Electronic Medical Information Request System for Field-generated Information Inquiries Rommel Fernandez,Barbara Schreiner,Edward Bezarro,Helen Yin Yu,Jimmy Thomas Black 2011 45(04) View Abstract
DIAJ Effect of Direct-to-Consumer Drug Advertising Exposure on Information Search Clive Mario Mendonca,David J McCaffrey,Benjamin F. Banahan III,Jonn P. Bently,Yi Yang 2011 45(04) View Abstract
DIAJ Using Real-time Data to Drive Better Decisions, Faster Paula Brown Stafford,Andrew Garrett 2011 45(04) View Abstract
DIAJ Covariate-adjusted Difference in Proportions From Clinical Trials Using Logistic Regression and Weighted Risk Differences Miaomiao Ge,L. Kathryn Durham,R. Daniel Meyer,Wangang Xie,Neal Thomas 2011 45(04) View Abstract
DIAJ Multiple-stage Sampling Procedure for Lot Release With Consideration of oth Manufacturer's and Consumer's Risk Boguang Zhen,Tie-Hua Ng,Henry Hsu 2011 45(04) View Abstract
DIAJ Optimal Sample Size Allocation in a Thorough QTc Study Joanne Zhang 2011 45(04) View Abstract
DIAJ Are Pharmacists a Viable Channel for Education About Clinical Trial Participation? Diane Simmons,Jill Chappell,Kenneth A. Getz,Zachary Hallinan,Brian P. Schrock,Dorothy L Smith 2011 45(04) View Abstract
DIAJ Phase 2 Clinical Development in Treating Chronic Diseases Naitee Ting 2011 45(04) View Abstract
DIAJ Evaluation of Data Entry Errors and Data Changes to an Electronic Data Capture Clinical Trial Database Jules T. Mitchel,Yong Joong Kim,Joonhyuk Choi,Glen D Park,Silvana Cappi,David Horn,Morgan Kist,Ralph B. D'Agostino 2011 45(04) View Abstract
DIAJ Variability in Protocol Design Complexity by Phase and Therapeutic Area Kenneth A. Getz,Rafael A. Campo,Kenneth I. Kaitin 2011 45(04) View Abstract
DIAJ Editor's Commentary: Additional Associate Editors, New Submission Category, and Meta-methodology Rick Turner 2011 45(04) View Abstract
DIAJ Proceedings of the DIA WOrkshop on Multiregional Clinical Trials, October 26-27, 2010 Ekopimo O. Ibia,Bruce Binkowitz 2011 45(03) View Abstract
DIAJ Factors Influencing Investigative SIte Willingness and Ability to Participate in Clinical Trials Mary Jo Lamberti,Rachael Zuckerman,Deborah Howe,Lisa E. Shapiro,Kenneth A. Getz 2011 45(03) View Abstract
DIAJ Assessing a Drug's Proarrhythmic Liability: An Oerview of Computer SImulation Modeling, Nonclinical Assays, and the Thorough QT/QTc Study Lawrence Z Satin,Timothy Lee Durham,Rick Turner 2011 45(03) View Abstract
DIAJ Time-Cost Optimization of Complex Clinical Trials Douglas Gregory 2011 45(03) View Abstract
DIAJ Call Handling in the Pharmaceutical Industry: A Benchmarking Survey Catherine J Nojiri,Chandni Patel 2011 45(03) View Abstract
DIAJ Conditional Type I Error Rate for Superiority Test Conditioned on Establishment of Noninferiority in Clinical Trials Jason Yuan,Tiejun Tong,Tie-Hua Ng 2011 45(03) View Abstract
DIAJ A Two-Stage Adaptive Design in Phase 2 Clinical Trials for Acute Treatment of Migraine Xiaoyin Frank Fan,Chris Assaid,Yang Joy Ge,Tony W. Ho 2011 45(03) View Abstract
DIAJ Statistical Analysis for Long-term Stability Studies with Multiple Storage Conditions Edwin Van den Heuvel,Osama Almalik,Michiel Nijhuis,Edward I. Warner 2011 45(03) View Abstract
DIAJ A Meta-analysis to Asess the FDA DAVP's TLOVR Algorithm in HIV Submissions Fraser Smith,Thomas Hammerstrom,Greg Soon,Susan Y Zhou,Baibai Chen,Yabling Mai,Kimberly A. Struble,Mohammad Huque 2011 45(03) View Abstract
DIAJ The Physicians' Labeling Rule: An Evaluation of Compliance Amy L. Ebel,Thomas G Cantu,Stuart Hobbs,Paula R. Rogenes,Melissa H Beaman,MaryAnn E Ziemba 2011 45(03) View Abstract
DIAJ Measuring the Incidence, Causes, and Repercussions of Protocol Amendments Kenneth A. Getz,Rachael Zuckerman,Anne B. Cropp,Anna L Hindle,Randy Krauss,Kenneth I. Kaitin 2011 45(03) View Abstract
DIAJ Substantial Evidence: When is a Single Trial Sufficient for Approval and Promotion? David Coutant,David Riggs,Elizabeth Van Sant Hoffman 2011 45(03) View Abstract
DIAJ FDAAA Basic Results Reporting: First Experience and Challenges Hans-Theo Forst,Robert Paarlberg,Elizabeth Roberts 2011 45(03) View Abstract
DIAJ Focus on the Cardia Safety Research Consortium Mitchell W. Krucoff 2011 45(03) View Abstract
DIAJ Why ABPM Should Be Mandatory in All Trials of Blood Pressure - Lowering Drugs Eoin O'Brien 2011 45(03) View Abstract
DIAJ Associates Editor's Commentary: Innovation Nation Peter J. Pitts 2011 45(03) View Abstract
DIAJ Editor's Commentary: Regulatory Science and the Science of Safety Rick Turner 2011 45(03) View Abstract
CHNNEWS Global Pharmaceutical Forum (In Chinese) Nov 01, 2012 Issue 9 View Abstract
CHNNEWS Global Pharmaceutical Forum (In Chinese) Aug 01, 2012 Issue 8 View Abstract
CHNNEWS Global Pharmaceutical Forum (In Chinese) May 01, 2012 Issue 7 View Abstract
CHNNEWS Global Pharmaceutical Forum (In Chinese) Feb 01, 2012 Issue 6 View Abstract
CHNNEWS Global Pharmaceutical Forum (In Chinese) Nov 01, 2011 Issue 5 View Abstract
CHNNEWS Global Pharmaceutical Forum (In Chinese) Aug 01, 2011 Issue 4 View Abstract
CHNNEWS Global Pharmaceutical Forum (In Chinese) May 01, 2011 Issue 3 View Abstract
GF Global Forum Feb 01, 2013 13(01) View Abstract
GF Global Forum Dec 01, 2012 12(06) View Abstract
GF Global Forum Oct 01, 2012 12(05) View Abstract
GF Global Forum Aug 01, 2012 12(04) View Abstract
GF Global Forum Jun 01, 2012 12(03) View Abstract
GF Global Forum Apr 01, 2012 12(02) View Abstract
GF Global Forum Feb 01, 2012 12(01) View Abstract
GF Global Forum Dec 01, 2011 11(06) View Abstract
GF Global Forum Oct 01, 2011 11(05) View Abstract
GF Global Forum Aug 01, 2011 11(04) View Abstract
GF Global Forum Jun 01, 2011 11(03) View Abstract
GF Global Forum Apr 01, 2011 11(02) View Abstract